Therapeutic Approaches to Target Inflammation in Type 2 Diabetes

被引:101
|
作者
Goldfine, Allison B. [1 ,2 ]
Fonseca, Vivian [3 ]
Shoelson, Steven E. [1 ,2 ]
机构
[1] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA
[3] Tulane Univ, Dept Med, Endocrinol Sect, New Orleans, LA 70118 USA
关键词
C-REACTIVE PROTEIN; NF-KAPPA-B; INDUCED INSULIN-RESISTANCE; SODIUM-SALICYLATE; CARDIOVASCULAR-DISEASE; GLYCEMIC CONTROL; IKK-BETA; RANDOMIZED-TRIAL; STATIN THERAPY; OBESE SUBJECTS;
D O I
10.1373/clinchem.2010.148833
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BACKGROUND: Chronic inflammation may participate in the pathogenesis of insulin resistance, type 2 diabetes, and cardiovascular disease and may be a common denominator that links obesity to these disease states. CONTENT: Epidemiologic studies have linked inflammatory biomarkers to incident diabetes and cardiovascular disease risk. Cellular and animal studies have provided support to the idea that inflammation mediates these disease processes, providing impetus to pharmacologically target these pathways for disease treatment and prevention. We review clinical strategies to target inflammation, with a focus on the antiinflammatory and antihyperglycemic effects of salicylates. SUMMARY: The evolving concept of diet-induced obesity driving insulin resistance, type 2 diabetes, and cardiovascular disease through immunologic processes provides new opportunities for the use of antiinflammatory strategies to correct the metabolic consequences of excess adiposity. (C) 2010 American Association for Clinical Chemistry
引用
收藏
页码:162 / 167
页数:6
相关论文
共 50 条
  • [31] Endoplasmic reticulum as a therapeutic target in type 2 diabetes: Role of phytochemicals
    Sajadimajd, Soraya
    Deravi, Niloofar
    Forouhar, Kimia
    Rahimi, Roja
    Kheirandish, Ali
    Bahramsoltani, Roodabeh
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 114
  • [32] Myocardial Calcium Handling in Type 2 Diabetes: A Novel Therapeutic Target
    Dattani, Abhishek
    Singh, Anvesha
    Mccann, Gerry P.
    Gulsin, Gaurav S.
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2024, 11 (01)
  • [33] PTPN2, a potential therapeutic target for type 1 diabetes?
    Liu, Shan-Shan
    Lou, Ji-Quan
    Ding, Ye
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2014, 58 (09) : 978 - 979
  • [34] PGC-1 activation: a therapeutic target for type 2 diabetes?
    Yuan, Daixiu
    Xiao, Dingfu
    Gao, Qian
    Zeng, Liming
    EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY, 2019, 24 (03) : 385 - 395
  • [35] NLRP3, a Potential Therapeutic Target for Type 2 Diabetes?
    Liu, Shan-Shan
    Ding, Ye
    Lou, Ji-Quan
    CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (04) : 391 - 392
  • [36] Novel therapeutic approach to target endothelial dysfunction in type 2 diabetes
    Sena, C. M.
    Pereira, A. M.
    Fernandes, R.
    Santos-Silva, D.
    Faustino, A.
    Ceica, R.
    CARDIOVASCULAR RESEARCH, 2014, 103
  • [37] NLRP3, a Potential Therapeutic Target for Type 2 Diabetes?
    Shan-Shan Liu
    Ye Ding
    Ji-Quan Lou
    Cardiovascular Drugs and Therapy, 2014, 28 : 391 - 392
  • [38] GPR30 Novel Therapeutic Target for Type 2 Diabetes
    Kumar, Rajesh
    Balhusizen, Alexander
    Salehi, Albert
    DIABETES, 2010, 59 : A444 - A444
  • [39] PGC-1α activation: a therapeutic target for type 2 diabetes?
    Daixiu Yuan
    Dingfu Xiao
    Qian Gao
    Liming Zeng
    Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 2019, 24 : 385 - 395
  • [40] The vascular smooth muscle cell: a therapeutic target in Type 2 diabetes?
    Porter, Karen E.
    Riches, Kirsten
    CLINICAL SCIENCE, 2013, 125 (3-4) : 167 - 182